Damora Therapeutics (DMRA) Total Non-Current Liabilities (2024 - 2026)

Damora Therapeutics (DMRA) has 3 years of Total Non-Current Liabilities data on file, last reported at $18.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 1070.39% year-over-year to $18.9 million; the trailing twelve-month figure through Mar 2026 stood at $18.9 million (up 1070.39% YoY), and the FY2025 full-year result was $20.1 million, up 1495.07% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $18.9 million, down from $20.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $20.1 million in Q4 2025 and bottomed at $1.3 million in Q4 2024.
• The 3-year median for Total Non-Current Liabilities is $2.7 million (2025), against an average of $7.9 million.
• The widest annual swing landed in 2025, when Total Non-Current Liabilities jumped 1495.07%; it then soared 1070.39% in 2026.
• A 3-year view of Total Non-Current Liabilities shows it stood at $1.3 million in 2024, then surged by 1495.07% to $20.1 million in 2025, then slipped by 6.04% to $18.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $18.9 million (Q1 2026), $20.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.

Peer Comparison